Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Johns Hopkins • NCI-CCC GU Tumor Board Question
How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?
Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?
Answer from: Medical Oncologist at Academic Institution
At the present time, they do not. The options of treatment in the mHSPC setting include ADT, NHT, and docetaxel only. There are some ongoing clinical trials evaluating the combination of immune therapy with PD-1/PD-L1 checkpoint inhibitors and docetaxel or NHTs currently. Some phase II clinical tria...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree. Some of the factors I also use to optimally select patients most likely to have a substantial survival benefit with sip-T are PSA levels (lower levels associated with greater benefit potentially from IMPACT, and Sartor et al., PMID 32111923 and Higano et al., PMID 31483485 from PROCEED...